Full Press Release Details
REGENERON REPORTS POSITIVE PHASE 3 DATA FOR IL-1 TRAP IN CAPS IL-1 Trap (rilonacept) Markedly Reduced Disease Activity in Patients with Rare Chronic Autoinflammatory Disease.
REGN
REGENERON REPORTS POSITIVE PHASE 3 DATA FOR IL-1 TRAP IN CAPS IL-1 Trap (rilonacept) Markedly Reduced Disease Activity in Patients with Rare Chronic Autoinflammatory Disease
Key Takeaway: REGENERON REPORTS POSITIVE PHASE 3 DATA FOR IL-1 TRAP IN CAPS IL-1 Trap (rilonacept) Markedly Reduced Disease Activity in Patients with Rare Chronic Autoinflammatory Disease
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema